Iron deficiency in non-dialysis chronic kidney disease

Kidney International

Volumn 75, Issue 7, 2009, Pages 752-754

  Fishbane, Steven ^a   Singh, Ajay K ^b  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ATENOLOL; CREATININE; FERRIC GLUCONATE; FERRITIN; FUROSEMIDE; HEMOGLOBIN; HYDROCHLOROTHIAZIDE; IRON; LEUPRORELIN; PROTEIN; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN; VALSARTAN;

ADULT; AFRICAN AMERICAN; AMENORRHEA; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CASE REPORT; CHRONIC KIDNEY DISEASE; CLINICAL EVALUATION; CLINICAL FEATURE; CREATININE BLOOD LEVEL; DIET; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FAMILY HISTORY; FATIGUE; FEMALE; FERRITIN BLOOD LEVEL; GLOMERULUS FILTRATION RATE; GYNECOLOGICAL EXAMINATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; HYSTERECTOMY; IRON DEFICIENCY ANEMIA; IRON THERAPY; KIDNEY FUNCTION; LIBIDO DISORDER; MENORRHAGIA; NEPHROSCLEROSIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RECURRENT DISEASE; TRANSFERRIN BLOOD LEVEL; URINALYSIS; UTERUS MYOMA;

ADULT; ANEMIA, IRON-DEFICIENCY; ANTINEOPLASTIC AGENTS, HORMONAL; FEMALE; HEMOGLOBINS; HUMANS; IRON; KIDNEY FAILURE, CHRONIC; LEIOMYOMA; LEUPROLIDE; MENORRHAGIA;

EID: 62349085563     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.292     Document Type: Article

References (17)

1. Ross SD, Allen IE, Henry DH et al. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature. Clin Ther 2006; 28: 801-831.
2. Drueke TB, Locatelli F, Clyne N, et al., CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084.
3. Parfrey PS, Foley RN, Wittreich BH et al. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 2005; 16: 2180-2189.
4. Erslev AJ, Besarab A. The rate and control of baseline red cell production in hematologically stable patients with uremia. J Lab Clin Med 1995; 126: 283-286.
5. Macdougall IC, Tucker B, Thompson J et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996; 50: 1694-1699.
6. Singh AK, Szczech L, Tang KL, et al., CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098.
7. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590.
8. Van Wyck DB, Stivelman JC, Ruiz J et al. Iron status in patients receiving erythropoietin for dialysis-associated anemia. Kidney Int 1989; 35: 712-716.
9. Fishbane S, Maesaka JK. Iron management in end-stage renal disease. Am J Kidney Dis 1997; 29: 319-333.
10. Gotloib L, Silverberg D, Fudin R et al. Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron. J Nephrol 2006; 19: 161-167.
11. Holley JL, Schmidt RJ, Bender FH et al. Gynecologic and reproductive issues in women on dialysis. Am J Kidney Dis 1997; 29: 685-690.
12. Bukulmez O, Doody KJ. Clinical features of myomas. Obstet Gynecol Clin North Am 2006; 33: 69-84.
13. Kjerulff KH, Langenberg P, Seidman JD et al. Uterine leiomyomas. Racial differences in severity, symptoms and age at diagnosis. J Reprod Med 1996; 41: 483.
14. Day Baird D, Dunson DB, Hill MC et al. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 2003; 188: 100.
15. Wegienka G, Baird DD, Hertz-Picciotto I et al. Self-reported heavy bleeding associated with uterine leiomyomata. Obstet Gynecol 2003; 101: 431-437.
16. Buttram Jr VC, Reiter RC. Uterine leiomyomata: etiology, symptomatology, and management. Fertil Steril 1981; 36: 433-445.
17. Friedman AJ, Barbieri RL, Doubilet PM et al. A randomized, double-blind trial of a gonadotropin releasing-hormone agonist (leuprolide) with or without medroxyprogesterone acetate in the treatment of leiomyomata uteri. Fertil Steril 1988; 49: 404-407.